ArticleFrontiers in pediatrics2026
Clinical characteristics and outcomes of neonatal heart failure: a single-center retrospective analysis.
Article in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Neonatal heart failure (HF) is a severe condition associated with high mortality because of immature organ function and limited cardiovascular reserve. However, studies focusing specifically on HF in neonates remain limited. This study aimed to characterize the clinical features of neonatal HF and identify factors associated with mortality, with additional analyses according to etiology and gestational age. Methods: This retrospective study included 89 neonates diagnosed with HF and admitted to our hospital between June 2016 and December 2025. Patients were classified into survival and death groups and were further stratified by etiology and gestational age (<34 weeks vs. ≥ 34 weeks). Logistic regression analyses were performed to identify factors associated with mortality, and model discrimination was evaluated using receiver operating characteristic (ROC) analysis. Results: The overall mortality was 31.5%. The primary causes of HF were critical congenital heart disease (28%), severe arrhythmia (13%), pulmonary hypertension (12%), extremely severe anemia (12%), and perinatal asphyxia (10%). Compared with the survival group, the death group had lower birth weight, lower Apgar scores, higher N-terminal pro-brain natriuretic peptide (NT-proBNP) levels, lower left ventricular ejection fraction (LVEF), and higher rate of fetal distress, respiratory failure, and shock. Multivariable analysis showed that fetal distress (OR, 7.70) and oliguria (OR, 7.32) were associated with higher mortality, whereas higher LVEF (OR per 1% increase, 0.94) was associated with lower mortality. The combined model had an AUC of 0.806 (95% CI, 0.702-0.909). In subgroup analysis, neonates born at <34 weeks had higher NT-proBNP levels, longer durations of invasive and non-invasive mechanical ventilation, longer hospital stays, higher rates of fetal distress, bronchopulmonary dysplasia and anemia, greater use of pulmonary surfactant, and higher mortality than those born at ≥34 weeks. No significant interactions by gestational age were observed for fetal distress, oliguria, or LVEF. Conclusions: Neonatal HF is associated with substantial mortality and is most commonly attributable to critical congenital heart disease, severe arrhythmia and other underlying conditions. Fetal distress and oliguria were independently associated with higher mortality, whereas higher LVEF was associated with lower mortality. Early recognition and targeted management are particularly important in preterm and other high-risk neonates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.